Giuseppina Barrera Selected Research

4-hydroxy-2-nonenal (4-hydroxynonenal)

1/2019	Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells.
7/2018	Lipid Peroxidation-Derived Aldehydes, 4-Hydroxynonenal and Malondialdehyde in Aging-Related Disorders.
12/2015	Improved Anti-Tumoral Therapeutic Efficacy of 4-Hydroxynonenal Incorporated in Novel Lipid Nanocapsules in 2D and 3D Models.
12/2013	The inclusion complex of 4-hydroxynonenal with a polymeric derivative of β-cyclodextrin enhances the antitumoral efficacy of the aldehyde in several tumor cell lines and in a three-dimensional human melanoma model.
10/2011	Nuclear factor erythroid 2-related factor-2 activity controls 4-hydroxynonenal metabolism and activity in prostate cancer cells.
1/2011	Induction of cell cycle arrest and DNA damage by the HDAC inhibitor panobinostat (LBH589) and the lipid peroxidation end product 4-hydroxynonenal in prostate cancer cells.
9/2010	4-hydroxynonenal, a lipid peroxidation product of dietary polyunsaturated fatty acids, has anticarcinogenic properties in colon carcinoma cell lines through the inhibition of telomerase activity.
3/2010	The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer.
11/2008	Down-regulation of Notch1 expression is involved in HL-60 cell growth inhibition induced by 4-hydroxynonenal, a product of lipid peroxidation.
6/2007	4-Hydroxynonenal and PPARgamma ligands affect proliferation, differentiation, and apoptosis in colon cancer cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giuseppina Barrera Research Topics

Disease

33	Neoplasms (Cancer) 10/2021 - 09/2004
5	Inflammation (Inflammations) 10/2021 - 11/2008
5	Urinary Bladder Neoplasms (Bladder Cancer) 10/2020 - 01/2018
4	Melanoma (Melanoma, Malignant) 12/2021 - 12/2013
4	Prostatic Neoplasms (Prostate Cancer) 01/2016 - 01/2011
4	Colonic Neoplasms (Colon Cancer) 01/2012 - 06/2007
3	Neoplasm Metastasis (Metastasis) 01/2016 - 03/2010
3	Atherosclerosis 01/2015 - 11/2008
2	Skin Neoplasms (Skin Cancer) 01/2021 - 01/2014
2	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2016
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 07/2018 - 05/2009
1	Pancreatic Neoplasms (Pancreatic Cancer) 10/2021
1	Cardiotoxicity 01/2020
1	Ovarian Neoplasms (Ovarian Cancer) 01/2020
1	Metabolic Bone Diseases (Osteopenia) 07/2018
1	Sarcopenia 07/2018
1	Drug-Related Side Effects and Adverse Reactions 11/2017
1	Anaplastic Thyroid Carcinoma 11/2017
1	Neurodegenerative Diseases (Neurodegenerative Disease) 02/2016
1	Mitochondrial Diseases (Mitochondrial Disease) 02/2016
1	Autoimmune Diseases (Autoimmune Disease) 06/2015
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2015
1	Hyperlipidemias (Hyperlipidemia) 01/2012
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2011
1	Hemorrhage 10/2011
1	Cardiomyopathies (Cardiomyopathy) 10/2011
1	Atherosclerotic Plaque (Atheroma) 10/2011
1	Neointima 10/2011

Drug/Important Bio-Agent (IBA)

13	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 01/2019 - 09/2004
11	Pharmaceutical PreparationsIBA 03/2021 - 10/2010
6	AntioxidantsIBA 10/2021 - 01/2012
6	Proteins (Proteins, Gene)FDA Link 10/2021 - 01/2005
6	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2021 - 03/2010
4	AldehydesIBA 07/2018 - 11/2008
4	CyclodextrinsIBA 11/2017 - 11/2012
4	Telomerase (Telomerase Reverse Transcriptase)IBA 09/2010 - 05/2006
3	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020 - 01/2016
3	CamptothecinIBA 11/2017 - 11/2012
3	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 11/2017 - 11/2012
3	Rosiglitazone (Avandia)FDA Link 01/2012 - 06/2007
3	LigandsIBA 01/2012 - 06/2007
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2021 - 10/2011
2	Cisplatin (Platino)FDA LinkGeneric 10/2020 - 03/2019
2	ailanthoneIBA 01/2020 - 03/2019
2	Messenger RNA (mRNA)IBA 01/2020 - 01/2018
2	AntibodiesIBA 01/2019 - 01/2016
2	1,3- benzothiazol- 2- yl(2- ((2- (3- pyridinyl)ethyl)amino)- 4- pyrimidinyl)acetonitrileIBA 01/2012 - 01/2012
2	Antineoplastic Agents (Antineoplastics)IBA 01/2012 - 01/2011
2	PPAR gammaIBA 06/2010 - 06/2007
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2021
1	CarbohydratesIBA 10/2021
1	LipidsIBA 10/2021
1	Deubiquitinating EnzymesIBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 03/2021
1	carbosilaneIBA 10/2020
1	Small Interfering RNA (siRNA)IBA 10/2020
1	Biological ProductsIBA 10/2020
1	Guanidine (Guanidine Nitrate)FDA Link 10/2020
1	Dendrimers (Dendrons)IBA 10/2020
1	6-bromo-2-naphthyl sulfate (BNS)IBA 01/2020
1	AnthracyclinesIBA 01/2020
1	Paclitaxel (Taxol)FDA LinkGeneric 01/2019
1	Cytotoxins (Cytolysins)IBA 01/2018
1	DNA AdductsIBA 01/2017
1	MetalsIBA 01/2017
1	DisulfidesIBA 05/2016
1	Glutathione (Reduced Glutathione)IBA 05/2016
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 02/2016
1	Mitochondrial DNA (mtDNA)IBA 02/2016
1	Fatty Acids (Saturated Fatty Acids)IBA 02/2016
1	Glutamic Acid (Glutamate)FDA Link 01/2016
1	AntiportersIBA 01/2016
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 01/2016
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2016
1	DNA (Deoxyribonucleic Acid)IBA 01/2016
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2016
1	Cystine (L-Cystine)IBA 01/2016
1	AlkaloidsIBA 01/2016
1	AntigensIBA 01/2016
1	NanocapsulesIBA 12/2015
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2015
1	Peptides (Polypeptides)IBA 01/2015
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2015
1	Tyrosine Kinase InhibitorsIBA 01/2015
1	Axitinib (AG 013736)IBA 01/2015
1	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2015
1	CrizotinibIBA 01/2015
1	Sunitinib (Sutent)FDA Link 01/2015
1	AndrogensIBA 11/2012
1	Topoisomerase I InhibitorsIBA 11/2012
1	Clofibrate FDA Link 01/2012
1	ciprofibrateIBA 01/2012
1	Fibric Acids (Fibrates)IBA 01/2012
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2011
1	Thromboplastin (Tissue Factor)IBA 10/2011
1	Histone Deacetylase InhibitorsIBA 01/2011

Therapy/Procedure

11	Therapeutics 12/2021 - 10/2011
1	Topical Administration 12/2015
1	Radiotherapy 01/2012
1	Heart Transplantation (Grafting, Heart) 10/2011